Drug Target Insights https://journals.aboutscience.eu/index.php/dti <p><strong>Drug Target Insights (DTI)</strong><em>&nbsp;</em>is an international, peer-reviewed, open access journal, covering current developments in all areas of the field of clinical therapeutics and focusing on molecular drug targets which include disease-specific proteins, receptors, enzymes, and genes. The journal seeks to elucidate the impact of new therapeutic agents on patient acceptability, preference, satisfaction and quality of life. The journal welcomes unsolicited article proposals. All articles are listed on PubMed and are freely available via PubMed Central.</p> <p>&nbsp;</p> en-US <p>Authors contributing to <strong>Drug Target Insights</strong> agree to publish their articles under&nbsp;the&nbsp;<a href="https://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener">Creative Common Attribution Non Commercial 4.0&nbsp;(CC-BY-NC 4.0)</a> license, which allows third parties&nbsp;to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.</p> lucia.steele@aboutscience.eu (Lucia Steele) production@aboutscience.eu (Silvia Minora) Tue, 07 Jan 2020 13:51:06 +0000 OJS 3.1.1.2 http://blogs.law.harvard.edu/tech/rss 60 Omalizumab as a Provoking Factor for Venous Thromboembolism https://journals.aboutscience.eu/index.php/dti/article/view/1415 A 43-year-old man with a history of severe extrinsic allergic asthma treated with once-monthly omalizumab (600 mg) for the last 15 months. He presented to the emergency room with a 2-week history of right lower limb pain and chest pleuritic pain. Computed tomography pulmonary angiography showed bilateral pulmonary embolism with right-sided pulmonary infarction and ultrasound of right lower limb confirmed distal deep vein thrombosis. No other known risk factors were identified. Treatment with omalizumab was stopped during hospitalization. The Naranjo Adverse Drug Reaction (ADR) Probability Scale classifies this as a probable ADR (score of 6). Omalizumab is a humanized monoclonal anti-IgE antibody indicated for the treatment of persistent moderate-to-severe asthma and certain chronic refractory urticaria. The EXCELS study (The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma), a postmarketing observational cohort study to assess clinical safety profile of omalizumab, showed a significant increase in venous thromboembolism. In conclusion, omalizumab has been associated with arterial and venous thromboembolic events, although the evidence is not definitive. Crhistian-Mario Oblitas, Francisco Galeano-Valle, Laura Vela-De La Cruz, Jorge Del Toro-Cervera, Pablo Demelo-Rodríguez ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc/4.0/ https://journals.aboutscience.eu/index.php/dti/article/view/1415 Thu, 04 Jul 2019 00:00:00 +0000 "Basic Concepts in Genetics and Pharmacogenomics for Pharmacists" https://journals.aboutscience.eu/index.php/dti/article/view/1416 This basic review of genetic principles will aid pharmacists in preparing for their eventual role of translating gene-drug associations into clinical practice. Genes, which are stretches of deoxyribonucleic acid (DNA) contained on the 23 pairs of human chromosomes, determine the size and shape of every protein a living organism builds. Variation in pharmacogenes which encode for proteins central to drug action and toxicity serves as the basis of pharmacogenomics (PGx). Important online resources such as PharmGKB.org, cpicpgx.org, and PharmVar.org provide the clinician with curated and summarized PGx associations and clinical guidelines. As genetic testing becomes increasingly affordable and accessible, the time is now for pharmacists to embrace PGx-guided medication selection and dosing to personalize and improve the safety and efficacy of drug therapy. Kathleen B Orrico ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc/4.0/ https://journals.aboutscience.eu/index.php/dti/article/view/1416 Tue, 03 Dec 2019 00:00:00 +0000 Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies https://journals.aboutscience.eu/index.php/dti/article/view/1417 Alzheimer disease is a neurodegenerative disease that is signified by cognitive decline, memory loss, and erratic behavior. Till date, no cure for Alzheimer exists and the current Alzheimer medications have limited effectiveness. However, herbal medicines may slow down the disease’s progression, which may hopefully reduce the number of cases in the years to come. Numerous studies have been done on characterizing the neuroprotective properties from plants belonging to Scrophulariaceae family, particularly Bacopa monnieri and its polyphenolic compounds known as bacosides. This review presents the findings on bacosides in therapeutic plants and their impact on Alzheimer disease pathology. These reports present data on the clinical, cellular activities, phytochemistry, and biological applications that may be used in new drug treatment for Alzheimer disease. Aimi Syamima Abdul Manap, Shantini Vijayabalan, Priya Madhavan, Yoke Yin Chia, Aditya Arya, Eng Hwa Wong, Farzana Rizwan, Umesh Bindal, Shajan Koshy ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc/4.0/ https://journals.aboutscience.eu/index.php/dti/article/view/1417 Wed, 31 Jul 2019 00:00:00 +0000 Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy https://journals.aboutscience.eu/index.php/dti/article/view/1418 Atrial fibrillation is the most common sustained cardiac arrhythmia, and its prevalence is increasing with age; also it is associated with significant morbidity and mortality. Rhythm control is advised in recent-onset atrial fibrillation, and in highly symptomatic patients, also in young and active individuals. Moreover, rhythm control is associated with lower incidence of progression to permanent atrial fibrillation. Vernakalant is a relatively new anti-arrhythmic drug that showed efficacy and safety in recent-onset atrial fibrillation. Vernakalant is indicated in atrial fibrillation (⩽7 days) in patients with no heart disease (class I, level A) or in patients with mild or moderate structural heart disease (class IIb, level B). Moreover, Vernakalant may be considered for recent-onset atrial fibrillation (⩽3 days) post cardiac surgery (class IIb, level B). Although it is mainly indicated in patients with recent-onset atrial fibrillation and with no structural heart disease, it can be given in moderate stable cardiac disease as alternative to Amiodarone. Similarly to electrical cardioversion, pharmacological cardioversion requires a minimal evaluation and cardioversion should be included in a comprehensive management strategy for better outcome. Antoine Kossaify ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc/4.0/ https://journals.aboutscience.eu/index.php/dti/article/view/1418 Wed, 03 Jul 2019 00:00:00 +0000 A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria https://journals.aboutscience.eu/index.php/dti/article/view/1419 OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations, pegvaliase injection. DATA SOURCES: Searches of MEDLINE (1946-September 1, 2018) were conducted using the terms pegvaliase and phenylalanine ammonialyase (PAL). Additional data were obtained from the prescribing information, the product dossier obtained from the manufacturer, and Clinicaltrials.gov. STUDY SELECTION AND DATA EXTRACTION: All English language articles related to pharmacology, pharmacokinetics, efficacy, or safety of the combination therapy in human subjects were reviewed. DATA SYNTHESIS: Pegvaliase is a pegylated PAL enzyme that converts phenylalanine to ammonia and trans-cinnamic acid. Blood phenylalanine levels were reduced by approximately 50% to 70% in patients receiving therapeutic doses of pegvaliase. However, most patients experienced adverse events. CONCLUSIONS AND RELEVANCE: The mainstay of therapy in phenylketonuria (PKU) has historically consisted of dietary restriction of phenylalanine. Pegvaliase injection is the first Food and Drug Administration (FDA)–approved enzyme substitution therapy for patients with PKU. The therapy may be a viable option for patients with documented blood phenylalanine >600 μmol/L who have failed existing management strategies. Tasmina Hydery, Valerie Azzopardi Coppenrath ##submission.copyrightStatement## https://creativecommons.org/licenses/by-nc/4.0/ https://journals.aboutscience.eu/index.php/dti/article/view/1419 Fri, 21 Jun 2019 00:00:00 +0000